EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu

doi:10.1016/j.jhep.2017.03.022

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.

Standard

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. / European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.

in: J HEPATOL, Jahrgang 67, Nr. 1, 07.2017, S. 145-172.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu 2017, 'EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.', J HEPATOL, Jg. 67, Nr. 1, S. 145-172. https://doi.org/10.1016/j.jhep.2017.03.022

APA

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu (2017). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J HEPATOL, 67(1), 145-172. https://doi.org/10.1016/j.jhep.2017.03.022

Vancouver

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J HEPATOL. 2017 Jul;67(1):145-172. https://doi.org/10.1016/j.jhep.2017.03.022

Bibtex

@article{93341f441da248c3bd04ddcfde032bc6,

title = "EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.",

abstract = "Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.",

keywords = "Cholangitis, Female, Humans, Liver Transplantation, Male, Practice Guidelines as Topic, Prognosis, Ursodeoxycholic Acid, Journal Article",

author = "{European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu}",

year = "2017",

month = jul,

doi = "10.1016/j.jhep.2017.03.022",

language = "English",

volume = "67",

pages = "145--172",

journal = "J HEPATOL",

issn = "0168-8278",

publisher = "Elsevier",

number = "1",

}

RIS

TY - JOUR

T1 - EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.

AU - European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu

PY - 2017/7

Y1 - 2017/7

N2 - Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.

AB - Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.

KW - Cholangitis

KW - Female

KW - Humans

KW - Liver Transplantation

KW - Male

KW - Practice Guidelines as Topic

KW - Prognosis

KW - Ursodeoxycholic Acid

KW - Journal Article

U2 - 10.1016/j.jhep.2017.03.022

DO - 10.1016/j.jhep.2017.03.022

M3 - SCORING: Journal article

C2 - 28427765

VL - 67

SP - 145

EP - 172

JO - J HEPATOL

JF - J HEPATOL

SN - 0168-8278

IS - 1

ER -